open access

Vol 69, No 3-4 (2019)
Review paper
Published online: 2019-10-31
Get Citation

Management of melanoma metastases in the brain

Piotr Rutkowski1, Dorota Kiprian23, Monika Dudzisz-Śledź1, Tomasz Świtaj1, Radosław Michalik4, Mateusz Spałek1, Katarzyna Kozak1, Tomasz Mandat4
DOI: 10.5603/NJO.2019.0018
·
Nowotwory. Journal of Oncology 2019;69(3-4):86-96.
Affiliations
  1. Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute – Oncology Center, Warsaw, Poland
  2. Department of Head & Neck Cancer, Maria Skłodowska-Curie Institute – Oncology Center, Warsaw, Poland
  3. Department of Oncology and Radiotherapy, Maria Skłodowska-Curie Institute – Oncology Center, Warsaw, Poland
  4. Department of Central Nervous System Tumours, Maria Skłodowska-Curie Institute – Oncology Center, Warsaw, Poland

open access

Vol 69, No 3-4 (2019)
Review article
Published online: 2019-10-31

Abstract

The basic principle for the diagnosis of melanoma metastases in the brain should be the management of multidisciplinary teams including at least a neurosurgeon, radiotherapist and clinical oncologist experienced in the treatment of melanoma and melanoma metastases in the CNS. Detection of brain lesions is associated with poor prognosis; metastases in the brain are the cause of death in 20–50% patients, and symptomatic tumours are a direct cause of death in about 90% patients. Treatment of melanoma with CNS metastases may include local management and/or systemic and symptomatic treat­ment. In the last 5 years, 10 new advanced melanoma drugs have been registered in Europe. Two-drug therapy anti-PD-1 and anti-CTLA-4 (nivolumab with ipilimumab) is the treatment of choice for asymptomatic melanoma metastases in the brain, while in the presence of BRAF mutations and asymptomatic metastases systemic treatment with BRAFi and MEKi may be the first-choice treatment.

Abstract

The basic principle for the diagnosis of melanoma metastases in the brain should be the management of multidisciplinary teams including at least a neurosurgeon, radiotherapist and clinical oncologist experienced in the treatment of melanoma and melanoma metastases in the CNS. Detection of brain lesions is associated with poor prognosis; metastases in the brain are the cause of death in 20–50% patients, and symptomatic tumours are a direct cause of death in about 90% patients. Treatment of melanoma with CNS metastases may include local management and/or systemic and symptomatic treat­ment. In the last 5 years, 10 new advanced melanoma drugs have been registered in Europe. Two-drug therapy anti-PD-1 and anti-CTLA-4 (nivolumab with ipilimumab) is the treatment of choice for asymptomatic melanoma metastases in the brain, while in the presence of BRAF mutations and asymptomatic metastases systemic treatment with BRAFi and MEKi may be the first-choice treatment.

Get Citation

Keywords

melanoma; brain; metastases; radiotherapy; immunotherapy; BRAF inhibitors; MEK inhibitors

About this article
Title

Management of melanoma metastases in the brain

Journal

Nowotwory. Journal of Oncology

Issue

Vol 69, No 3-4 (2019)

Article type

Review paper

Pages

86-96

Published online

2019-10-31

DOI

10.5603/NJO.2019.0018

Bibliographic record

Nowotwory. Journal of Oncology 2019;69(3-4):86-96.

Keywords

melanoma
brain
metastases
radiotherapy
immunotherapy
BRAF inhibitors
MEK inhibitors

Authors

Piotr Rutkowski
Dorota Kiprian
Monika Dudzisz-Śledź
Tomasz Świtaj
Radosław Michalik
Mateusz Spałek
Katarzyna Kozak
Tomasz Mandat

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl